Connect with us

Business Partnerships

Tilray (TLRY) to Acquire Calgary-based 420 Investments (Four20), Valued Up to $110 Million

Published

on

Tilray (TLRY) to Acquire Calgary-based 420 Investments (Four20), Valued Up to $110 Million

Vertically-integrated cannabis firm, Tilray announced on Thursday, August 29, that is has entered a definitive agreement with Canadian cannabis retailer, 420 Investments Ltd. (FOUR20), in which the former will acquire what’s left of the latter’s securities.

Tilray alongside Toronto-based cannabis and global consumer brands, High Park will be coming together to leverage FOUR20’s retail business revealed the press release. This is a long-term effort that is expected to enter all Canadian provincial markets moving forward.

According to Tilray’s Chief Corporate Development Officer, Andrew Pucher, “With FOUR20, we will elevate the retail experience for consumers by offering the best quality-tested products while preparing for the next way of legalized product launches.”

As per the deal, Tilray will have to pay up $70 million in its respective class 2 common shares, combined with an extra $40 million in common shares based on some of FOUR20’s milestones attained.

The entirety of the “closing of transaction” is expected to take place by the end of 2020’s first quarter.

Andrew is a full-time professional writer in Canada with over 8 years of esteemed experience. He is one of the best cannabis health researchers, polished legal investigators and active CBD news reporters we have at TOC. While being featured in hundreds of health, technology, science, and even bitcoin publications; Andrew's now on the frontline of the Canadian cannabis culture and will continue breaking down everything so easily your grandma can understand hemp and CBD.

Continue Reading

Ultimate CBD Guide


Disclaimer

ultimate-cbd-products-company-guidepopular-cbd-health-benefits best-cannabidiol-guide-resources hemp guide

TimesofCBD is the most active daily CBD news publication featuring the latest cannabis industry stories and marijuana market trends. As the leader in CBD-centric content curation, we invite all readers to come for the headlines and stay for the insights. Quality is the top priority when presenting user guides, analyzing product reviews and reporting fact-checked news announcements. All information is for educational and informational purposes only. Disclaimer.

Got news? Email contact@timesofcbd.com

Copyright © 2020 TimesofCBD.com | Latest CBD News, Cannabis Guides and Marijuana Trends
Note: Always seek real additional medical advice and consultation with a professional healthcare practitioner before considering any CBD. No statements found on this website have underwent Food and Drug Administration evaluation. The efficacy of any products or claims made have never been approved by the FDA either. No products shall ever be intended to diagnose, treat or cure any disease or prevent any ailment.